By: Dr. Shane Kurth, D.C., BCN
Co-Owner, Radiant Results
Updated September 2026

This guide was prepared by the clinical team at Radiant Results. It examines the research on red light therapy (photobiomodulation) as an adjunctive option for joint discomfort associated with menopause. Topics covered include the mechanism of estrogen-driven joint inflammation, what the evidence actually supports, and who should consult a physician before beginning sessions. This post does not claim that red light therapy treats menopause as a condition, and it does not substitute for individualized medical advice. Readers whose joint pain is undiagnosed or associated with other symptoms should seek evaluation from a qualified healthcare provider before starting any new modality.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. It is not a substitute for evaluation, diagnosis, or treatment by a licensed healthcare provider. If joint pain is severe, sudden, or accompanied by swelling, redness, fever, or other symptoms, consult a physician before pursuing any therapeutic option.

Red Light Therapy for Menopause Joint Pain in Lake Norman

Red light therapy for menopause joint pain — clinically, photobiomodulation (PBM) applied to estrogen-driven arthralgia — does not treat menopause as a condition. Controlled trials in musculoskeletal pain populations do support its use as an adjunctive tool, however, and the evidence base for PBM in musculoskeletal and arthritic pain is moderate-to-strong. Evidence for menopause-specific applications extrapolates from those broader trials. For women in the Lake Norman area navigating perimenopause or postmenopause, that distinction matters: the tool is evidence-informed and well-tolerated, but it works alongside — not instead of — medical evaluation and established care.

Key Takeaways

• A 2024 meta-analysis pooling 321 studies and 482,067 middle-aged women found that joint and muscular discomfort had the highest pooled prevalence of any menopausal symptom — 65.43% — exceeding even hot flashes. Musculoskeletal pain is, by the numbers, the most common symptom of the menopausal transition, yet it remains among the least discussed in public health messaging.
• Research has found that deletion of estrogen receptors in female mice results in cartilage damage, osteophytosis, and changes in subchondral bone — suggesting estrogens have a protective role in maintaining joint homeostasis. When estrogen declines at menopause, that protection wanes across multiple joint tissues simultaneously.
• Near-infrared wavelengths (810–850nm) penetrate 2–5cm into tissue — sufficient to reach joint capsules in the knees, hips, and shoulders — where they support cellular processes that modulate the inflammatory environment.
• Evidence for PBM in musculoskeletal and arthritic pain is moderate-to-strong from multiple controlled trials. Evidence specific to menopause-related joint pain is emerging, extrapolated from those broader musculoskeletal studies. Honest framing of that distinction is part of what the Radiant Results clinical team considers responsible practice.
• Women with undiagnosed joint pain — particularly symmetrical swelling, morning stiffness lasting more than 30 minutes, or systemic symptoms such as fatigue alongside joint complaints — should seek physician evaluation before beginning sessions. Autoimmune conditions can mimic estrogen-related arthralgia and require a different care pathway.

Why Menopause Joint Pain Is More Common Than Hot Flashes

Most conversations about menopause center on hot flashes. The clinical data tell a different story.

A 2024 systematic review and meta-analysis pooling 321 studies and 482,067 middle-aged women found that the highest pooled prevalence of any menopausal symptom was joint and muscular discomfort at 65.43% (Fang et al., 2024, PMC11220992). Hot flashes — the symptom most associated with menopause in popular culture — came in lower, at 52.65%. This reversal is clinically significant and consistently underreported in patient education.

The scale of this problem is considerable. As ovarian estrogen production diminishes in midlife, more than 47 million women worldwide enter the menopause transition annually. A 2020 systematic review published in Neural Plasticity found that musculoskeletal pain affects an estimated 71% of perimenopausal women — with an odds ratio of 1.63 (95% CI: 1.35–1.96) compared to premenopausal women (Lu et al. 2020, PMC7710408).

The joints most commonly reported as affected are the hips, knees, hands and fingers, shoulders, and lower spine. Many women describe the onset as unexpectedly abrupt: joints that had been asymptomatic suddenly feel achy, stiff, and slow to recover after ordinary activity.

Why does this go underdiscussed? Most clinical education and patient-facing menopause information centers on vasomotor symptoms and mood changes. Joint pain gets attributed to age rather than to the hormonal transition driving it — leaving women without a clear explanation and, consequently, without a clear path toward addressing it.

Understanding that menopause joint pain has a well-characterized biological mechanism is the first step toward choosing interventions logically matched to that mechanism.

The Estrogen-Joint Connection: What’s Happening in the Body

Estrogen is not a narrowly reproductive hormone. It operates throughout the musculoskeletal system — with anti-inflammatory properties, a role in maintaining cartilage integrity, regulatory influence over the synovial lining of joints, and modulatory effects on pain sensitivity across the nervous system.

Estrogen receptors are present in cartilage, subchondral bone, synovium, muscles, and tendons, as documented in a 2013 review in Joint Bone Spine (Martín-Millán & Castañeda, DOI: 10.1016/j.jbspin.2012.11.008). This distribution explains why estrogen decline affects so many joint structures simultaneously. It is not a single-point failure — it is a system-wide shift in the hormonal environment that has been supporting those tissues throughout adult life.

The downstream effects are measurable. Loss of estrogen increases reactive oxygen species and pro-inflammatory cytokines in joint tissue. The resulting inflammatory environment directly affects joint structure: cartilage thins, synovial fluid quality changes, and pain sensitivity rises. The same Joint Bone Spine review reports that deletion of estrogen receptors in female mice results in cartilage damage, osteophytosis, and changes in subchondral bone — strongly suggesting estrogens have a protective role in joint homeostasis (Martín-Millán & Castañeda 2013, PubMed 23352515).

Estrogen’s relationship to joint health is not perfectly linear or fully resolved. Conflicting data exist on the link between endogenous sex steroid levels and osteoarthritis risk. Estrogen appears to have pro- or anti-inflammatory effects depending on biological context. The science is well-supported but not uniform — and honest clinical communication accounts for that nuance.

The practical significance for women in this transition is meaningful. The photobiomodulation-arthralgia connection has a documentable biological pathway, and that pathway informs which therapeutic approaches are logically appropriate to consider alongside medical management. For a broader look at red light therapy for joint and musculoskeletal pain, that service resource covers general applications in more detail.

What Is the Musculoskeletal Syndrome of Menopause?

Most women going through the menopausal transition know something is happening to their joints. Fewer know that this cluster of symptoms has been named in the clinical literature.

In 2024, Wright, Schwartzman, Itinoche, and Wittstein published a paper in Climacteric (DOI: 10.1080/13697137.2024.2380363) naming the “musculoskeletal syndrome of menopause.” The syndrome encompasses arthralgia (joint aching and stiffness), accelerated muscle loss (sarcopenia), reduced bone mineral density, and faster progression of osteoarthritis — all driven by the same hormonal withdrawal. Per that paper, more than 70% of women will experience musculoskeletal symptoms through this transition, and 25% will be meaningfully disabled by them (Wright et al. 2024, Climacteric).

Naming matters clinically. When a symptom cluster has a recognized name and a defined mechanism, it earns appropriate attention from providers and patients alike. Women who frame their experience within the musculoskeletal syndrome of menopause have a stronger basis for a targeted clinical conversation.

This syndrome is distinct from classical osteoarthritis (though the two overlap) and distinct from inflammatory arthritis, which has autoimmune rather than estrogen-deficiency origins. Critically, it can begin as early as perimenopause — before most women would expect age-related joint changes to appear.

Women who are unsure which category their joint pain falls into should consult a physician before beginning any new therapeutic program. The autoimmune differential is addressed in detail in the safety section below.

How Photobiomodulation Addresses Estrogen-Driven Joint Inflammation

Red light therapy (photobiomodulation, PBM) acts at the cellular level through a well-characterized mechanism — not through heat and not through surface effects alone.

As Hamblin’s 2017 review in AIMS Biophysics (PMC5523874) establishes, PBM involves the use of red and near-infrared light to stimulate healing, relieve pain, and reduce inflammation. The primary chromophores — cellular components that absorb photons and initiate downstream effects — are cytochrome c oxidase in the mitochondria and calcium ion channels. Secondary effects include increased ATP production, a transient reactive oxygen species burst that triggers cellular adaptation, increased nitric oxide, and modulated calcium levels. These downstream effects collectively reduce the inflammatory environment in affected tissue and support tissue repair.

The relevance to estrogen-driven joint inflammation is mechanistically direct. Estrogen loss raises pro-inflammatory cytokines and reactive oxygen species in joint tissue. PBM acts on precisely that inflammatory environment by downregulating inflammatory signaling at the cellular level. A 2023 comprehensive review in the International Journal of Molecular Sciences (PMC10531845) reports that when PBM is applied in activated inflammatory cells, inflammatory markers are consistently decreased across both preclinical and clinical studies.

Wavelength specificity matters practically. Near-infrared light (810–850nm) penetrates 2–5cm into tissue — sufficient to reach the joint capsule, synovium, and surrounding musculature of the knee, hip, and shoulder. Red light (~630–660nm) penetrates approximately 8–10mm, supporting surrounding soft tissue and superficial musculature. At Radiant Results, both wavelengths are delivered simultaneously in a single 15-minute full-body session — addressing joint structures and surrounding tissue together, rather than requiring spot treatment of individual joints.

A 2023 review in Frontiers in Cell and Developmental Biology (Zhang & Ji, DOI: 10.3389/fcell.2023.1286025) notes that PBM therapy for osteoarthritis provides biological stimulatory effects primarily by enhancing cytochrome c oxidase activity, fostering cell proliferation, fibroblast activation, and tissue regeneration. The approach is drug-free, non-invasive, and carries a favorable safety profile — characteristics that are particularly relevant for women managing multiple symptoms during the menopausal transition.

What the Evidence Shows — and Where It’s Still Emerging

The evidence for PBM in joint pain is real and meaningful. It is also more nuanced than a simple headline implies. Honest evidence grading is part of responsible clinical communication.

Moderate-to-Strong Evidence: Musculoskeletal Pain Broadly and Knee Osteoarthritis

Multiple randomized controlled trials and systematic reviews support PBM for reducing pain and improving function across musculoskeletal conditions, though results vary by device, wavelength, and dosing protocol. Hamblin’s 2017 review (PMC5523874) documents PBM’s reduction of inflammatory markers across musculoskeletal tissue types. Knee osteoarthritis shares significant mechanistic overlap with estrogen-deficiency arthralgia — including low-grade joint inflammation, cartilage degeneration, and subchondral bone remodeling — and is one of the most studied areas of the musculoskeletal PBM evidence base, with a review of the RCT literature reporting benefit for pain and function in many (though not all) trials (Zhang & Ji 2023).

Preclinical / Emerging Evidence: Rheumatoid Arthritis

Ryu et al. (2023, Frontiers in Immunology, DOI: 10.3389/fimmu.2023.1122581) examined PBM’s effects in synoviocytes and animal models of rheumatoid arthritis, characterizing photobiomodulation as a potential adjunctive resource based on anti-inflammatory activity in joint tissue. This evidence is preclinical (cell and mouse models), and clinical results are moderated by variability in device type, wavelength, and dosing across trials. Results are more consistent for pain reduction than for structural joint changes.

Emerging / Extrapolated: Menopause-Specific Arthralgia

No large randomized controlled trials have studied photobiomodulation specifically in women with menopause-related arthralgia as the primary study population. The application extrapolates from the broader musculoskeletal evidence reviewed above. This extrapolation is clinically logical — the inflammatory mechanism is shared — but it means the evidence strength for this specific population is accurately classified as emerging rather than established. Women considering PBM for menopause joint pain are making an evidence-informed decision based on a coherent mechanism and a strong adjacent evidence base, not a decision based on menopause-specific proof of efficacy.

What to Expect: A Realistic Timeline for Joint Pain Support

Timeline observations reflect typical client-reported experiences and published musculoskeletal PBM trial timelines. They are not guaranteed outcomes. Individual results vary based on baseline inflammation, session consistency, joint type, and concurrent care.

Safety: Who Should Consult a Physician Before Starting

The safety profile of photobiomodulation is generally favorable. “Generally favorable” is not the same as “appropriate for everyone without evaluation.” This section outlines who should seek physician clearance before beginning sessions, and why.

The Autoimmune Differential — Why It Matters for Perimenopause Joint Inflammation

Perimenopause is a period of elevated autoimmune disease incidence. Rheumatoid arthritis, psoriatic arthritis, lupus-related arthropathy, and Sjögren’s-associated joint disease can all emerge or worsen during the menopausal transition — and can present identically to estrogen-deficiency arthralgia at onset.

The following features are more consistent with autoimmune-origin joint pain than with estrogen-related arthralgia. Each warrants physician evaluation before beginning any therapeutic program:

• Symmetrical joint involvement in multiple joints simultaneously — both hands, both wrists, both knees — is more consistent with rheumatoid arthritis than with estrogen-deficiency arthralgia, which tends to be diffuse and migratory.
• Morning stiffness lasting more than 30–60 minutes, particularly stiffness that improves with movement but returns after prolonged inactivity, is a hallmark of inflammatory arthritis.
• Joint swelling, warmth, or visible redness over a joint warrants physician evaluation.
• Systemic symptoms — fatigue, low-grade fever, unexplained weight loss, dry eyes or dry mouth — accompanying joint pain warrant prompt physician evaluation.
• Joint pain that preceded perimenopause, or that is rapidly worsening, warrants physician evaluation.

Any woman with undiagnosed joint pain, or joint pain accompanied by the features above, is encouraged to seek physician evaluation and medical clearance before beginning sessions.

RLT Safety for Diagnosed Autoimmune Conditions

For women with a confirmed autoimmune joint condition — rheumatoid arthritis, psoriatic arthritis, lupus-related arthropathy — the published safety profile of PBM is generally favorable. Sessions should be undertaken with the explicit knowledge and approval of the treating rheumatologist. PBM does not suppress the immune system in the manner of DMARDs or biologics, but it does modulate inflammatory signaling. Any modification to the inflammatory environment in an autoimmune patient benefits from the awareness of the clinician managing that condition.

General Contraindications and Consultation Guidance

The following situations require physician or specialist clearance before beginning red light therapy sessions. These are not absolute bars to treatment for most people — but each requires individual medical review as the appropriate starting point:

• Active or suspected malignancy of any type
• Personal history of hormone-sensitive cancers (breast, endometrial, ovarian) — not a known direct RLT risk, but oncology team awareness and explicit clearance are warranted
• Photosensitizing medications, including certain antibiotics, diuretics, NSAIDs, and retinoids
• Isotretinoin — current use or within the preceding six months
• Implanted electronic devices in or near the treatment area, including pacemakers, spinal cord stimulators, and cochlear implants
• Active skin infections or open wounds in the treatment area
• Pregnancy
• Autoimmune conditions with an active flare — sessions should be deferred until the flare is managed and the treating provider has approved resumption

When to See Your Doctor First
Seek physician evaluation BEFORE starting red light therapy sessions if: joint pain is undiagnosed; joint pain is severe, rapidly worsening, or accompanied by swelling, warmth, or redness; systemic symptoms — fever, fatigue, unexplained weight loss — are present alongside joint pain; a personal history of cancer is relevant; or any of the contraindications listed above apply.

The FDA provides regulatory context for photobiomodulation devices and device classification. Women with specific questions about device regulatory status are encouraged to review that resource alongside consultation with their provider.

What to Expect at a Radiant Results Session in Lake Norman

The Radiant Results Dahlia bed is a full-body medical-grade light therapy device delivering red (~630–660nm) and near-infrared (~810–850nm) wavelengths simultaneously in a 15-minute session. The client lies comfortably in the bed while both wavelengths are delivered across the full body surface.

For menopause joint pain specifically, full-body delivery carries a practical advantage that targeted panels do not. Estrogen-driven musculoskeletal symptoms rarely present in just one location. The woman with hip stiffness in the morning is often also managing hand aching and shoulder tightness. A full-body protocol addresses the systemic inflammatory environment rather than requiring spot treatment of individual joints in sequence.

The Dahlia bed includes a facial protection pad, so women who want the full-body anti-inflammatory benefit of a session without unguarded facial light exposure have a design-level solution built into the equipment itself.

Women in the Lake Norman area — including those coming from Mooresville, Huntersville, Cornelius, and Denver, NC — are often managing physically active lives alongside the joint changes of the menopausal transition. Golf rounds that feel different in the hips and wrists. Lake activities that leave shoulders aching longer than they used to. Morning runs that now require an extended warmup. In clinical experience, women in this area are not looking to slow down — they are looking for tools that support their recovery capacity so they can stay active through the transition.

What clients in a consistent PBM protocol typically describe at four to six weeks: reduced post-activity stiffness, improved morning mobility, and in some cases less reliance on NSAIDs for joint discomfort day-to-day. At six to eight weeks, more sustained comfort through the day and improved sleep quality emerge as PBM reduces the joint pain that had been interrupting rest. These observations are consistent with published musculoskeletal PBM trial timelines and reflect the clinical pattern the Radiant Results team observes — they are not guaranteed outcomes.

Results vary. Factors that influence individual outcomes include baseline inflammation level, session consistency, concurrent lifestyle practices — movement, protein intake, sleep — and whether the joint pain is primarily estrogen-related or has a concurrent cause requiring its own medical management. A typical initial session frequency for joint pain support involves multiple visits per week; the Radiant Results team provides a schedule recommendation suited to individual goals at the first visit.

Visit Radiant Results — Lake Norman

19824 W Catawba Ave, Suite G, Cornelius, NC 28031 · 704-255-4885

Serving Cornelius, Mooresville, Huntersville, Davidson, and Denver, NC.

Women in the Lake Norman area interested in exploring red light therapy as part of a menopause joint care plan can begin with the $79 New Patient Special, which includes a full-body Dahlia bed session and an initial consultation with the clinical team. Claim the $79 New Patient Special.

RLT as Part of a Menopause Joint Care Plan: What Works Alongside It

Red light therapy is an adjunct — not a replacement for medical evaluation, hormone therapy for appropriate candidates, or other established care options. Stating that plainly is not a concession; it is the kind of honest clinical framing that makes a recommendation trustworthy.

Low-impact movement — walking, swimming, cycling, and resistance training — is among the most evidence-supported interventions for musculoskeletal symptoms during the menopausal transition. Movement maintains muscle mass, which reduces mechanical load on joints. It also stimulates synovial fluid circulation, supporting joint lubrication and cartilage nutrition.

Adequate dietary protein is relevant because muscle loss accelerates during the estrogen-withdrawal phase of menopause. Maintaining muscle mass is one of the most effective ways to protect the joints beneath it.

Omega-3 fatty acids provide anti-inflammatory dietary support with a consistent evidence base for joint comfort. Vitamin D and calcium support bone mineral density — which estrogen decline affects directly and which contributes to structural joint health.

Hormone therapy (HRT/MHT) — for appropriate candidates — addresses the root hormonal cause of estrogen-deficiency arthralgia in a way that photobiomodulation does not. Research indicates that pro-inflammatory cytokine expression is attenuated by estrogen replacement (Martín-Millán & Castañeda 2013, PubMed 23352515). HRT decisions should be made collaboratively with a qualified gynecologist or women’s health provider. RLT can be a useful adjunct for women on HRT, women not on HRT, and women who are still evaluating hormonal options.

Rheumatologist or orthopedist consultation for women with moderate-to-severe joint symptoms remains important — particularly for ruling out OA progression, autoimmune disease, or structural joint issues that require specific medical management.

PBM is strongest as a tool that supports the body’s anti-inflammatory processes and cellular energy production. It works alongside movement, nutrition, and medical management — not instead of any of them. Women who pair consistent sessions with these evidence-based lifestyle supports consistently report more favorable outcomes than those using PBM alone.

Frequently Asked Questions

Does red light therapy actually help with menopause joint pain?

The evidence supports red light therapy (photobiomodulation) as an adjunctive tool for joint inflammation, including the inflammation driven by estrogen decline during menopause. Multiple controlled trials demonstrate PBM’s ability to reduce inflammatory signaling in joint tissue, support cellular energy production via cytochrome c oxidase, and reduce pain in musculoskeletal conditions including osteoarthritis. Evidence specific to menopause-related arthralgia extrapolates from those broader musculoskeletal studies — dedicated menopause-specific RCTs are not yet established.

Why do joints hurt so much since entering menopause or perimenopause?

Estrogen receptors are present in cartilage, subchondral bone, synovium, muscles, and tendons. When estrogen declines during perimenopause, that protective influence wanes across all of those tissues simultaneously. Loss of estrogen increases reactive oxygen species and pro-inflammatory cytokines in joint tissue, which produces the aching, stiffness, and slower recovery many women notice. This is not simply aging — it is a hormonally mediated process now described clinically as the musculoskeletal syndrome of menopause (Wright et al. 2024, Climacteric).

Which wavelength of red light is best for deep joint pain?

Near-infrared wavelengths (810–850nm) penetrate 2–5cm into tissue — reaching the joint capsule, synovium, and surrounding musculature of the knees, hips, and shoulders. Red light (~630–660nm) penetrates approximately 8–10mm, supporting surrounding soft tissue and superficial musculature. For joint pain specifically, near-infrared is the primary functional wavelength for reaching the joint structures themselves. At Radiant Results, both wavelengths are delivered simultaneously in a 15-minute full-body session.

How long before results are noticeable for joint pain with red light therapy?

Published musculoskeletal PBM trial timelines and clinical experience generally align around a four-to-eight-week window for meaningful, sustained changes in joint comfort. Some women notice post-session ease in movement during the first few weeks. The first one to three sessions represent a cellular priming phase; anti-inflammatory effects accumulate over consistent exposure. Results vary based on joint type, baseline inflammation, session frequency, and concurrent care.

Is red light therapy safe if I have rheumatoid arthritis or another autoimmune condition?

For women with a confirmed autoimmune joint condition, the published safety profile of PBM is generally favorable. Sessions should be undertaken with the explicit approval of the treating rheumatologist, since PBM modulates inflammatory signaling and any modification to the inflammatory environment in an autoimmune patient benefits from the awareness of the managing clinician. Emerging preclinical research characterizes photobiomodulation as a potential adjunctive resource for rheumatoid arthritis (Ryu et al. 2023, Frontiers in Immunology). Women with undiagnosed joint pain that may have autoimmune features should seek physician evaluation before beginning sessions.

Where can women in the Lake Norman area access medical-grade red light therapy?

Radiant Results serves the Lake Norman area — including Mooresville, Huntersville, Cornelius, and Denver, NC — with medical-grade full-body red light therapy using the Dahlia bed. Women new to photobiomodulation can begin with the $79 New Patient Special, which includes a full-body session and an initial consultation with the clinical team. Claim the $79 New Patient Special.

Sources

1. Fang Y, et al. “Mapping global prevalence of menopausal symptoms among middle-aged women: a systematic review and meta-analysis.” BMC Public Health. 2024. PMID: 38956480. PMC11220992. DOI: 10.1186/s12889-024-19280-5.
2. Lu C, et al. “Musculoskeletal Pain During the Menopausal Transition: A Systematic Review and Meta-Analysis.” Neural Plasticity. 2020. PMC7710408.
3. Martín-Millán M, Castañeda S. “Estrogens, osteoarthritis and inflammation.” Joint Bone Spine. 2013. PMID: 23352515. DOI: 10.1016/j.jbspin.2012.11.008.
4. Wright VJ, Schwartzman JD, Itinoche R, Wittstein J. “The musculoskeletal syndrome of menopause.” Climacteric. 2024;27(5):466–472. PMID: 39077777. DOI: 10.1080/13697137.2024.2380363.
5. Hamblin MR. “Mechanisms and Applications of the Anti-Inflammatory Effects of Photobiomodulation.” AIMS Biophysics. 2017. PMC5523874.
6. “The Mechanisms and Efficacy of Photobiomodulation Therapy for Arthritis: A Comprehensive Review.” International Journal of Molecular Sciences. 2023. PMC10531845.
7. Zhang Y, Ji Q. “Current advances of photobiomodulation therapy in treating knee osteoarthritis.” Frontiers in Cell and Developmental Biology. 2023;11:1286025. PMID: 38033853. DOI: 10.3389/fcell.2023.1286025.
8. Ryu JH, Park J, Kim B-Y, Kim Y, Kim NG, Shin Y-I. “Photobiomodulation ameliorates inflammatory parameters in fibroblast-like synoviocytes and experimental animal models of rheumatoid arthritis.” Frontiers in Immunology. 2023;14:1122581. DOI: 10.3389/fimmu.2023.1122581.
9. FDA — Light Therapy Devices. https://www.fda.gov/medical-devices/home-use-devices/light-therapy-devices